TaiheCap
天汇资本
elsewhere's corpus doesn't carry a standalone profile of TaiheCap — the fund only surfaces as a co-investor in other firms' portfolio announcements. What can be said from that trail: it participated in antibody-discovery CRO Biointron's nearly RMB 500 million Series B in August 2022, alongside Cornerstone Capital, Jifeng Capital, Gaorong, and over ten other institutions ; and in a round for Shize Biotech announced around the turn of 2025, led by Tailong/Taikun Capital, per a FreeS Family funding roundup . Both deals sit in biotech, but two name-drops aren't enough to establish TaiheCap's focus, size, or history — that material simply isn't in the corpus yet.
AI-generated — may contain errors, please verify.
Coverage
As the year draws to a close, five companies secure new funding to carry momentum into 2025 | FreeS Family Funding News Vol. 21
Looking forward to working alongside more outstanding founders.
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
